New IO Targets and Resistance Mechanisms of Immune Checkpoint-Based Therapies
At the ASCO 2021 virtual annual meeting, Dr. Antoni Ribas from UCLA, Dr. Patrick Alexander Ott from Dana Farber together with Dr. Kurt A. Schalper from Yale University teamed to discuss resistance mechanisms of checkpoint inhibitors, potential therapeutic combinations, neoantigen landscape, tumor mutational burden, and the role of tumor microenvironment in cancer immunotherapy.
Therapeutic resistance can be of two types, viz, primary resistance- wherein patients generally do not respond to therapy, and acquired resistance- where patients respond initially but still undergo disease progression.
Therapeutic resistance can be of two types, viz, primary resistance- wherein patients generally do not respond to therapy, and acquired resistance- where patients respond initially but still undergo disease progression.
GO Prime with only $1.49 now
LATEST
World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access
2025-04-25
Astellas’ Transformation Journey: From Merger to Global Player, Betting on the Edge of Innovation and Risk?
2025-04-25
Steminent Stands Ready to Showcase Novel MSC-based Therapy for Spinocerebellar Ataxia at Global Stage
2025-04-24